If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is critical for timely intervention. Building on decades of pharmaceutical safety research, this page provides a clear overview of PML symptoms, monitoring protocols, and what the latest science says about risk management.
Tysabri (natalizumab) is a biologic medication approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning that states Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FDA adverse-event reports most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, drug ineffective, urinary tract infection, pain, balance disorder, hypoesthesia, pain in extremity, muscular weakness, nasopharyngitis, nausea, dizziness, mobility decreased, stress, cognitive disorder, muscle spasms, depression, and arthralgia (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they reflect the range of adverse events reported by patients. The clinical presentation of PML can include progressive weakness on one side of the body, clumsiness, vision changes, changes in thinking, memory, and orientation, confusion, and personality changes. Diagnosis typically involves brain MRI showing characteristic lesions and detection of JCV DNA in cerebrospinal fluid. The timeline between Tysabri exposure and PML onset can vary. The boxed warning notes that risk increases with longer treatment duration, especially beyond 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have occurred after as few as eight doses, as seen in the Crohn's disease clinical trial (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For patients who develop PML, the consequences are severe. The boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). There is no specific antiviral treatment for PML; management focuses on restoring immune function, often by discontinuing Tysabri and, in some cases, using plasma exchange to accelerate drug clearance. Regarding the adequacy of warnings, the prescribing information includes a boxed warning that explicitly states the increased risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program is designed to ensure that patients and healthcare providers are informed about this risk. However, some patients may still develop PML despite these warnings, raising questions about whether the warnings are sufficient to allow fully informed decision-making. For affected patients and their families, legal considerations may arise. An attorney specializing in Tysabri-related PML cases can help evaluate whether the manufacturer provided adequate warnings and whether the patient's specific risk factors were properly considered. Factors such as the presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use are central to assessing risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm is also critical, as PML can develop after varying treatment durations. In summary, Tysabri carries a well-documented risk of PML, a severe and often fatal brain infection. The prescribing information identifies specific risk factors and mandates monitoring and immediate drug cessation if PML is suspected. Patients who develop PML may face life-altering consequences, and legal consultation may be appropriate to explore whether the warnings and risk management were adequate in their specific case.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic medication used to treat multiple sclerosis and Crohn's disease. It carries a boxed warning because it increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The risk is higher in patients with anti-JCV antibodies, longer treatment duration (especially over 2 years), and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML symptoms include progressive weakness on one side of the body, clumsiness, vision changes, confusion, memory problems, and personality changes. Diagnosis is made through brain MRI showing characteristic lesions and detection of JC virus DNA in cerebrospinal fluid (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Patients who developed PML after Tysabri use may consult an attorney specializing in pharmaceutical litigation to evaluate whether the manufacturer provided adequate warnings and whether the patient's specific risk factors were properly considered. Legal claims may focus on failure to warn or inadequate risk management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.